|
answer text |
<p>Maraviroc (brand name Celsentri) is currently authorised through the European centralised
procedure for the treatment of patients who are infected with HIV type 1. It is used
in combination other HIV medicines.</p><p>The Medicines and Healthcare products Regulatory
Agency which is responsible for the regulation of medicines in the United Kingdom
is not aware of any application for maraviroc for use in patients with progressive
multifocal leukoencephalopathy (PML) and cannot therefore comment on the efficacy
of this drug in patients with PML.</p><p> </p><p> </p>
|
|